Tempus Expands Strategic Collaboration with Bristol Myers Squibb
Business Wire•23/10/2026•09:00 ET
5
Key Highlights
- ➤BMS licenses Tempus multimodal oncology data through 2031
- ➤BMS becomes one of Tempus’s largest licensors of de-identified oncology data
- ➤BMS gains Tempus’ Lens Platform for AI-driven oncology drug development
- ➤Tempus and BMS expand collaboration across oncology and neuroscience initiatives
Expert Statements
Eric Lefkofsky, Founder and CEO of Tempus
“This strategic collaboration is an important step forward in using AI to advance the discovery of new treatment options and potentially improve patient outcomes”
Eric Lefkofsky, Founder and CEO of Tempus
“By uniting our vast multimodal data asset with dedicated GPU power inside our Lens Platform, we are equipping BMS with the AI tools necessary to decode complex biology. Together, we aren't just speeding up drug discovery, we are laying the foundation for a future where precision oncology becomes the standard of care for every patient.”
Tempus Expands Strategic Collaboration with Bristol Myers Squibb
Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus’s largest licensors of de-identified oncology data.
Get started
Create a free account to read the full story.